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The importance of the second messen-
gers calcium (Ca2) and diacylglycerol
(DAG) in platelet signal transduction was
established more than 30 years ago.
Whereas protein kinase C (PKC) family
members were discovered as the targets
of DAG, little is known about the molecu-
lar identity of the main Ca2 sensor(s). We
here identify Ca2 and DAG-regulated gua-
nine nucleotide exchange factor I
(CalDAG-GEFI) as a critical molecule in
Ca2-dependent platelet activation.
CalDAG-GEFI, through activation of the
small GTPase Rap1, directly triggers inte-
grin activation and extracellular signal-
regulated kinase-dependent thrombox-
ane A2 (TxA2) release. CalDAG-GEFI–
dependent TxA2 generation provides
crucial feedback for PKC activation and
granule release, particularly at threshold
agonist concentrations. PKC/P2Y12 sig-
naling in turn mediates a second wave of
Rap1 activation, necessary for sustained
platelet activation and thrombus stabiliza-
tion. Our results lead to a revised model
for platelet activation that establishes one
molecule, CalDAG-GEFI, at the nexus of
Ca2-induced integrin activation, TxA2
generation, and granule release. The pref-
erential activation of CalDAG-GEFI over
PKC downstream of phospholipase C ac-
tivation, and the different kinetics of
CalDAG-GEFI– and PKC/P2Y12-mediated
Rap1 activation demonstrate an unex-
pected complexity to the platelet activa-
tion process, and they challenge the cur-
rent model that DAG/PKC-dependent
signaling events are crucial for the initia-
tion of platelet adhesion. (Blood. 2009;
114:2506-2514)
Introduction
Platelet thrombus formation at sites of vascular injury is a complex
and dynamic process that occurs in several phases.1,2 Platelet
preactivation and tethering (transient adhesion) are mediated by the
interaction of glycoprotein (GP) lb with matrix-bound von
Willebrand factor, particularly in conditions of high shear. Platelet
activation and firm adhesion are then triggered by collagen exposed
in the vessel wall and/or locally generated thrombin. Sustained
integrin activation and the formation of stable thrombi further
depend on persistent costimulatory signaling provided by the
second wave agonists, thromboxane A2 (TxA2) and adenosine
5-diphosphate (ADP), which are released from activated platelets.3-5
The central biochemical event in platelet aggregation is the
agonist-induced inside-out activation of IIb3 integrin. Most
platelet agonists initiate intracellular signaling through the activa-
tion of phospholipase C (PLC), followed by the generation of the
second messengers calcium (Ca2) and diacylgycerol (DAG).
DAG is critical for protein kinase C (PKC) activation, a key event
in platelet granule release and integrin activation. Platelets express
at least 6 PKC isoforms, which have activating as well as inhibitory
roles in platelet activation.6-10 Early studies with calcium iono-
phores established a role of Ca2 in integrin activation, TxA2
generation, and granule release.11-13 Initially, Ca2-binding classi-
cal isoforms of PKC were suggested as the cell’s main signal
integrators for elevated intracellular Ca2 concentrations ([Ca2]i).
However, more recent studies using calcium chelators in combina-
tion with broad range PKC inhibitors identified an independent
Ca2-sensitive signaling pathway that acts synergistically with
PKC in the activation of integrin IIb3.14,15 Whereas the role of
Ca2 and DAG/PKC in various aspects of platelet activation has
been well documented, the molecular nature of the Ca2 sensor(s)
and the interplay between Ca2- and DAG-driven signaling
pathways have been less clearly defined.
In our recent work, we have identified Ca2- and DAG-
regulated guanine nucleotide exchange factor I (CalDAG-GEFI,
RasGRP2) as a key molecule regulating Ca2-dependent activation
of integrins in platelets.16,17 CalDAG-GEFI contains binding sites
for Ca2 and DAG and a GEF domain catalyzing the activation of
small GTPases of the Ras family, in particular Rap1 and Rap2.18 In
platelets, Rap1B accounts for 90% of the total Rap protein,19 and its
importance in IIb3 activation has recently been demonstrated in
Rap1B-deficient mice.20 Importantly, studies in cell types other
than platelets demonstrated only very weak affinity of the C1
domain of CalDAG-GEFI for DAG in platelets,21,22 suggesting that
it is predominantly regulated by binding of Ca2 to its hand
domains. Several of our recent studies with platelets isolated from
CalDAG-GEFI–deficient mice support this assumption. First, plate-
let aggregation induced by Ca2 ionophores, but not by the phorbol
ester phorbol myristate acetate (DAG mimetic), was sensitive to
CalDAG-GEFI expression.16 Second, CalDAG-GEFI was critical
for the rapid, but reversible activation of Rap1 in thrombin-
activated platelets, a process that depends on increased [Ca2]i.17
And third, CalDAG-GEFI–dependent integrin activation occurred
independent of signaling by PKC/P2Y12, suggesting that CalDAG-
GEFI is part of the Ca2-dependent pathway of platelet activation,
which synergizes with signaling by PKC in integrin activation.14,15
Rap1 has been extensively studied for its role in the regulation
of cell adhesion.23 In cells other than platelets, Rap1 also regulates
cellular differentiation and proliferation via pathways that involve
the regulation of the mitogen-activated protein kinase (MAPK)
cascade.24 Rap1 either interferes with Ras-mediated extracellular
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signal-regulated kinase (ERK) activation or it activates ERK
independently of Ras in a cell context–dependent manner.25 In
certain neurons, regulation of Rap1-dependent MAPK activation
has been found to be directly downstream of CalDAG-GEFI.26,27 In
platelets, ERK-MAPKs have been implicated in the phosphoryla-
tion of cytosolic phospholipase A2 (cPLA2),28 a key enzyme in the
formation of arachidonic acid and thus TxA2.29-31 Interestingly,
both Ca2 and PKC signaling contribute to ERK1/2 activation.32
In the present study, we investigated the mechanisms by which
signaling by CalDAG-GEFI and PKC affects various aspects of
platelet activation induced via stimulation of the collagen receptor,
GPVI. Our studies demonstrate that CalDAG-GEFI is the main
Ca2 sensor that links increases in intracellular Ca2 levels to the
signaling pathways regulating integrin activation and ERK-MAPK
signaling/TxA2 formation in stimulated platelets. CalDAG-GEFI
mediates the first wave of platelet TxA2 formation, which provides
critical feedback for the activation of PKC and granule release.
P2Y12/Gi-dependent signaling induces a second wave of platelet
activation, which is required for the formation of stable platelet
aggregates.
Methods
Reagents and antibodies
Lovenox (enoxaparin sodium; Sanofi-Aventis), heparin-coated capillaries
(VWR), bovine serum albumin (fraction V), prostacyclin, human fibrinogen
(type I), and U0126 (mitogen-activated protein kinase kinase [MEK]
inhibitor; all from Sigma-Aldrich), 2-methylthio-adenosine 5-monophos-
phate triethylammonium salt hydrate (2-MesAMP, P2Y12 inhibitor;
BioLog), complete protease inhibitor mixture lacking ethylenediaminetet-
raacetic acid (Roche Applied Science), Ro31-8220 (PKC inhibitor; EMD
Chemicals), fibrillar collagen type I (Chronlog), calcein AM (Invitrogen),
RalGDS-RBD coupled to agarose beads and polyvinylidene fluoride
membranes (Millipore), U46619 (Cayman Chemical), acetylsalicylic acid
(Bayer), and 3H-serotonin (Amersham Biosciences) were purchased. Con-
vulxin (Cvx) was provided by K. Clemetson (Theodor Kocher Institute,
University of Berne). Monoclonal blocking antibody to murine IIb3,
Leo.H4, and monoclonal antibody directed against the activated form of
murine IIb3, JON/A-PE, were purchased from Emfret Analytics. Anti-
phospho(Thr202/Tyr204)-ERK, anti-ERK, and anti–phospho-(Ser) PKC sub-
strate antibody were purchased from Cell Signaling Technology. Anti-Rap1
was purchased from Santa Cruz Biotechnology.
Mice
CalDAG-GEFI/ mice16 on a C57B1/6 background were obtained from
the lab of Ann Graybiel (Massachusetts Institute of Technology) and were
bred in the mouse facility of Thomas Jefferson University. Experimental
procedures were approved by the Animal Care and Use Committee of
Thomas Jefferson University.
Platelet preparation
Blood was drawn from the retroorbital plexus into heparinized tubes.
Platelet-rich plasma was obtained by centrifugation at 100g for 5 minutes.
Platelet-rich plasma was centrifuged at 700g in the presence of prostacyclin
(2 g/mL) for 5 minutes at room temperature. After 2 washing steps,
pelleted platelets were resuspended at the concentration of 4  108
platelets/mL in modified Tyrode buffer (137 mM NaCl, 0.3 mM Na2HPO4,
2 mM KCl, 12 mM NaHCO3, 5 mM N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid, 5 mM glucose, pH 7.3) containing 0.35% bovine
serum albumin and 1 mM CaCl2.
Flow cytometry
Washed platelets were diluted in Tyrode buffer containing 1 mM CaCl2,
activated with Cvx and/or U46619 in the presence of JON/A-PE33 for
10 minutes, and studied immediately by flow cytometry. MesAMP was
added before platelet stimulation to block P2Y12 receptor signaling.
Aggregometry
Light transmission was measured in washed platelets activated in the
presence of 50 g/mL fibrinogen under stirring conditions at 37°C.
Inhibitors and agonists were added at the indicated concentrations, and light
transmission was recorded more than 10 minutes on a Chrono-log 4-
channel optical aggregation system (Chrono-log).
Thromboxane generation assay
Platelets were stimulated in standard aggregometry. At different time
points, 50 L of sample was withdrawn and 5 mM EDTA (ethylenediami-
netetraacetic acid)/1 mM aspirin was added. The cells were removed by
centrifugation, and thromboxane B2 (TxB2) levels were determined in the
supernatant by enzyme immunoassay (Assay Designs). TxB2 is the stable
product of the nonenzymatic hydration of TxA2, which itself has a half-life
of only 37 seconds under physiologic conditions.
Serotonin release
Washed platelets were incubated for 30 minutes at 37°C with 3H-serotonin
(2 Ci [0.074 MBg]/mL). After one washing step, platelets were resus-
pended (4  108 platelets/mL) in modified Tyrode buffer containing 1 M
imipramine and 1 mM CaCl2. Platelets were stimulated in standard
aggregometry. At the indicated time points, 50 L of sample was with-
drawn, and the reaction was stopped with an equal volume of 0.1 M
EDTA/2% formaldehyde. The samples were then centrifuged for 5 minutes
at 10 000g, and the supernatants were used for scintillation counting of
3H-serotonin. Total or 100% 3H-serotonin secretion was defined as the
3H-serotonin in samples lysed with 0.5% Triton X-100.
Rap1 and ERK activation
Platelets were stimulated in standard aggregometry for various times.
Reactions were stopped with ice-cold 2 lysis buffer (100 mM Tris/HCl,
pH 7.4, 400 mM NaCl, 5 mM MgCl2, 2% Nonidet P-40, 20% glycerol, and
complete protease inhibitor mixture lacking ethylenediaminetetraacetic
acid). Cell lysis was completed on ice for 15 minutes. A total of 200 L of
sample was immediately solubilized in sample buffer (75 mM Tris/HCl,
pH 6.8, 10% sodium dodecyl sulfate, 5% 2-mercaptoethanol, 0.004%
bromphenol blue) for the detection of phosphorylated ERK2 and total
ERK1/2 levels. A total of 200 L of lysate was used to detect activated
Rap1 according to the protocol previously described.16 Briefly, Rap1-
adenosine triphosphate (GTP) was precipitated from lysates using RalGDS-
RBD beads (Millipore).
Western blotting
Total protein lysates and precipitated proteins were separated on 4% to 12%
or 4% to 20% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
gradient gels and transferred to polyvinylidene fluoride membranes.
Phosphorylated and nonphosphorylated ERK1/2 and Rap1 were detected
with rabbit polyclonal antibodies. PKC-dependent protein phosphorylation
was evaluated using a rabbit anti–phospho-(Ser) PKC substrate antibody.
After incubation with anti–rabbit antibodies, conjugated to horseradish
peroxidase (Vector Laboratories), immunoreactivity was detected by West-
ern Lightning enhanced chemiluminescence (G-Biosciences).
Flow chamber assay
Whole blood anticoagulated with heparin (30 U/mL low molecular weight
heparin; Lovenox) was perfused at a shear rate of 400 seconds1 over
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bovine type I collagen–coated glass slides (PureCol, 300 g/mL; Inamed
Biomaterials) in a parallel-plate flow chamber. Platelet adhesion was
visualized with a 20/0.45 PlanFluor objective on a Nikon Ti-U inverted
microscope (Nikon Instruments Inc) equipped with a Retiga EXL mono-
chrome camera (QImaging). Images were analyzed using Nikon NIS
Elements AR 3.0 software and processed with Photoshop CS3. After
5 minutes of perfusion, the number of firmly adherent platelets was
determined in 3 separate areas (0.02 mm2). The experiment was repeated
3 times for each genotype.
Statistics
Results are reported as mean plus or minus SEM. Statistical significance
was assessed by unpaired 2-tailed Student t test. A P value less than .05 was
considered significant.
Results
The generation of TxA2 and ADP is crucial for platelet aggregation
in response to stimulation of the main collagen receptor, GPVI. To
test whether CalDAG-GEFI is critical for GPVI-induced formation
of second wave mediators, we first studied TxA2 generation in
CalDAG-GEFI/ platelets activated with the nonphysiologic
agonist. As shown in Figure 1A, TxA2 generation, as measured by
the formation of its stable analog TxB2, was completely abolished
in knockout platelets stimulated with low dose Cvx (100 ng/mL).
In response to high dose (500 ng/mL) of the agonist, TxA2
production was delayed and reached approximately 3-fold lower
Figure 1. CalDAG-GEFI is central to Cvx-dependent TxA2 generation. Washed platelets in the presence of 1 mM Ca2 and 50 g/mL fibrinogen were stimulated under
stirring conditions at 37°C (standard aggregometry) with (A,C) low (LD, 100 ng/mL) or (B,D) high (HD, 500 ng/mL) dose Cvx. Samples were withdrawn at the indicated time
points to measure the levels of TxB2, the stable product of the nonenzymatic hydration of TxA2. (A-B) TxB2 levels in the supernatant of WT (black line, F) or CalDAG-GEFI/
(knockout [KO], gray line, Œ) platelets activated in the presence (open symbols) or absence (filled symbols) of 75 M 2-MesAMP (P2Y12 inhibitor). Data shown are
mean  SEM (n 	 4). At a high dose of Cvx (B), significantly higher levels of TxB2 were detected at all time points in the supernatant of activated WT platelets compared with
WT/MesAMP, KO, or KO/MesAMP platelets. (C-D) Aggregation traces representative of 3 independent experiments. (E) WT (f) or CalDAG-GEFI–deficient (u) platelets were
stimulated with LD (100 ng/mL) or HD (750 ng/mL) Cvx in the presence or absence of 2-MesAMP. Binding of JON/A-PE was measured to determine the level of IIb3 activation
by flow cytometry. n 	 6. (F) TxB2 release from WT and CalDAG-GEFI/ (KO) platelets stimulated for 10 minutes with HD Cvx in the presence () or absence (f) of 40 g/mL
IIb3 blocking antibody Leo.H4. Data shown are mean  SEM (n 	 3), *P 
 .05, **P 
 .01, ***P 
 .001.
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concentrations in CalDAG-GEFI/ platelets compared with WT
(Figure 1B).
Previous studies demonstrated that ADP/P2Y12 signaling is a
major component of thrombin-induced TxA2 generation.31 Thus,
we investigated the role of the ADP/P2Y12 signaling pathway
downstream of the collagen receptor GPVI. The P2Y12 inhibitor,
2-MesAMP, impaired TxA2 release from Cvx-activated WT plate-
lets to a similar extent as the absence of CalDAG-GEFI. Moreover,
2-MesAMP completely abolished the residual TxA2 release ob-
served in Cvx-stimulated CalDAG-GEFI/ platelets (Figure 1B),
demonstrating a synergistic role of P2Y12–dependent and CalDAG-
GEFI–dependent signaling in GPVI-dependent TxA2 generation.
The time course of TxA2 generation showed a striking correla-
tion with integrin activation as monitored by standard aggregom-
etry (Figure 1C-D). Direct assessment of IIb3 activation in
platelets stimulated with low dose Cvx, using an antibody against
the activated form of the receptor (JON/A-PE33), demonstrated
completely inhibited activation of IIb3 in CalDAG-GEFI/
platelets (Figure 1E). At high dose of Cvx, CalDAG-GEFI/
platelets showed a small, but significant increase in JON/A-PE
binding, which was abolished in the presence of 2-MesAMP. To
exclude the possibility that the defect in TxA2 generation was
secondary to the defect in integrin activation observed in knockout
platelets, we determined TxA2 release from platelets activated in
the presence or absence of a blocking antibody to IIb3. Integrin
inhibition marginally reduced TxA2 production in both WT and
CalDAG-GEFI/ platelets. However, there was a significant
difference in TxA2 release between CalDAG-GEFI–deficient and
IIb3-inhibited WT platelets (P 
 .05; Figure 1F), demonstrating
that CalDAG-GEFI contributes to TxA2 generation independent of
its role in integrin inside-out signaling.
To further characterize the signaling pathways that lead to
CalDAG-GEFI–dependent and CalDAG-GEFI–independent TxA2
generation, we compared the kinetics of Rap1 activation with that
of ERK-MAPK phosphorylation. Both ERK phosphorylation and
Rap1 activation were completely abolished in CalDAG-GEFI/
platelets activated with 100 ng/mL Cvx (Figure 2A). When acti-
vated with 500 ng/mL Cvx, activation of both Rap1 and ERK was
delayed (Figure 2B), and the residual activation observed in
knockout platelets was abolished upon pretreatment of the cells
with 2-MesAMP (Figure 2C).
In addition to Cvx, we studied platelets stimulated with fibrillar
type I collagen (Figure 3). Collagen activation led to approximately
40% more TxA2 generation in WT platelets compared with Cvx.
TxA2 release in collagen-activated CalDAG-GEFI–deficient plate-
lets was markedly impaired and delayed (Figure 3A). The kinetics
of TxA2 release correlated well with those of Rap1 and ERK
activation (Figure 3C), suggesting that CalDAG-GEFI is crucial for
the first wave of TxA2 release. Pretreatment of knockout platelets
with 2-MesAMP markedly reduced, but did not abolish collagen-
induced TxA2 release (Figure 3A), although activation of both
ERK and Rap1 was completely inhibited under these experimental
conditions (Figure 3D).
To confirm the role of ERK signaling in Rap1-dependent TxA2
generation, we compared our results with 2-MesAMP–pretreated
CalDAG-GEFI/ platelets (Rap1 activation completely blocked)
with those obtained with WT platelets pretreated with the MEK
inhibitor, U0126.34 Pretreatment with U0126 completely inhibited
ERK phosphorylation (not shown) and TxA2 release in Cvx-
activated WT platelets (Figure 3E). In collagen-activated platelets,
U0126 abolished ERK phosphorylation (not shown), whereas it
reduced TxA2 release by approximately 60%. Thus, the GPVI/
Rap1/ERK-dependent signaling pathway accounts for approxi-
mately 60% of the TxA2 production in collagen-activated
platelets.
Based on these results, we speculated that the defect in TxA2
generation explains why CalDAG-GEFI/ platelets fail to aggre-
gate in response to low concentrations of Cvx, and that addition of
exogenous TxA2 could restore aggregation of Cvx-stimulated
knockout platelets. As expected, aggregation was observed in
CalDAG-GEFI/ platelets stimulated with threshold concentra-
tions of the thromboxane mimetic, U46619, and low dose Cvx, but
not with either agonist alone (Figure 4A). Aggregation was
reversed by pretreatment with a broad range PKC inhibitor,
Ro31-8220, or the P2Y12 inhibitor 2-MesAMP. Consequently,
binding of JON/A-PE to mutant platelets costimulated with Cvx
and U46619 was significantly higher than in mutant platelets
activated with either agonist alone, or platelets activated with Cvx
and U46619 in the presence of 2-MesAMP (Figure 4B). Thus, in
CalDAG-GEFI/ platelets activated with a low dose of a GPVI
agonist, TxA2 is required to trigger integrin activation through the
CalDAG-GEFI–independent, but PKC/P2Y12–dependent pathway.
To confirm this hypothesis, we evaluated the phosphorylation
state of downstream targets of PKC, such as pleckstrin-1 (PLEK),35
in stimulated platelets. In WT platelets, PLEK phosphorylation was
observed in response to threshold doses of Cvx or U46619. In
contrast, PLEK phosphorylation was markedly reduced in CalDAG-
GEFI–deficient platelets activated with low dose Cvx or low dose
U46619. However, PLEK phosphorylation was restored in CalDAG-
GEFI/ platelets activated with both Cvx and U46619 (Figure
4C). To test whether impaired integrin activation at low Cvx
concentrations could be the result of defective release and cosignal-
ing by ADP, we next studied dense granule release in CalDAG-
GEFI–deficient platelets. Release of 3H-labeled serotonin from
platelets activated under stirring conditions was measured (Figure
4D). Low dose Cvx stimulation induced the rapid release of
Figure 2. CalDAG-GEFI and P2Y12 synergize in Cvx-dependent activation of Rap1 and ERK-MAPK. Washed WT or CalDAG-GEFI/ (knockout [KO]) platelets were
stimulated in standard aggregometry with (A) 100 ng/mL (low dose [LD]) or (B-C) 500 ng/mL (high dose [HD]) Cvx. Platelets were activated in the presence (C) of 75 M
2-MesAMP to inhibit signaling by P2Y12. Rap1-GTP and phospho-ERK were determined in samples withdrawn at the indicated time points. Total ERK1/2 levels (bottom panel)
were determined as a loading control. Results are representative of 3 individual experiments.
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serotonin from WT, but not CalDAG-GEFI/, platelets. However,
a threshold dose of U46619 could partially restore Cvx-induced
secretion. Secretion under these conditions was dependent on PKC
activation, as it was blocked by the broad range PKC inhibitor,
Ro31-8220.
Based on these findings, we speculated that TxA2 released from
WT platelets might be able to induce the aggregation of CalDAG-
GEFI/ platelets activated with low dose collagen. As shown in
Figure 5A, addition of 10% WT platelets partially restored
aggregation of CalDAG-GEFI/ platelets (62%  23% of WT).
In contrast, WT platelets pretreated with aspirin were unable to
restore aggregation of knockout platelets (0% of WT). Further-
more, 10% of WT platelets failed to restore aggregation of
CalDAG-GEFI/ platelets pretreated with a IIb3 blocking
antibody (5%  1% of WT). Thus, TxA2 released from the WT
platelets provided a stimulatory signal required for IIb3 activation
in CalDAG-GEFI/ platelets activated with low dose collagen. To
confirm the generation of aggregates consisting of both WT and
CalDAG-GEFI/ platelets, we repeated these studies with calcein
green-labeled WT and calcein red-labeled CalDAG-GEFI/ plate-
lets (Figure 5B). Fixed aggregates were visualized by fluorescence
microscopy. As expected, green-labeled WT platelets recruited a
large number of red-labeled CalDAG-GEFI/ platelets into the
aggregates. Pretreatment with an IIb3 blocking antibody, how-
ever, almost completely blocked the incorporation of knockout
platelets.
To validate our findings under conditions of physiologic flow,
we tested the effect of exogenous thromboxane on the adhesion of
CalDAG-GEFI/ platelets to collagen in flow chamber studies
(Figure 6A). Whereas WT platelets formed thrombi on the collagen
surface, only few CalDAG-GEFI/ platelets were able to firmly
adhere to collagen under these conditions. Addition of U46619 led
to significantly more firm adhesion of CalDAG-GEFI/ platelets
(Figure 6B). The effect of U46619 was reversed by pretreating
CalDAG-GEFI/ platelets with 2-MesAMP, suggesting that exog-
enous thromboxane promotes adhesion of knockout platelets via an
ADP/P2Y12-dependent mechanism.
Discussion
Our studies establish a revised model for platelet activation by
collagen (Figure 7). The key elements of this new model are as
follows: (1) the central role of one molecule, CalDAG-GEFI, in
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Figure 3. CalDAG-GEFI is critical for collagen-dependent TxA2 generation. (A) Time course of TxB2 release from WT (black line, circle) or CalDAG-GEFI/ (knockout
[KO], gray line, triangle) platelets. Cells were stimulated with 25 g/mL fibrillar type I collagen under stirring conditions in the presence (open symbols) or absence (filled
symbols) of 75 M 2-MesAMP. Data shown are mean  SEM (n 	 4). Significantly higher levels of TxB2 were detected at indicated time points in the supernatant of activated
WT platelets compared with KO or KO/MesAMP platelets. (B) Aggregation traces representative of 3 independent experiments. (C-D) Time course of ERK (top panel) and
Rap1 (middle panel) activation in platelets activated with collagen in the presence (D) or absence (C) of 75 M 2-MesAMP. Representative of 3 independent experiments.
(E) TxB2 levels in the supernatant of WT platelets stimulated for 10 minutes with 500 ng/mL Cvx (high dose [HD] Cvx), or 25 g/mL fibrillar collagen (HD collagen). Cells were
activated in the presence () or absence (f) of 50 M U0126 (MEK inhibitor). U0126 totally abolished ERK phosphorylation in response to Cvx or collagen (data not shown).
Data are shown as mean  SEM. The amount of TxB2 released from collagen-activated platelets was defined as 100%. n 	 3. *P 
 .05, **P 
 .01, ***P 
 .001.
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Ca2-dependent platelet activation; (2) the preferential activation
of CalDAG-GEFI over PKC downstream of PLC activation; (3) the
importance of Rap1, activated by CalDAG-GEFI and P2Y12
signaling, in integrin activation and TxA2 generation; (4) the
critical role of CalDAG-GEFI in TxA2 release and subsequent PKC
activation, degranulation, and activation of P2Y12/Gi signaling;
and (5) the kinetic differences between CalDAG-GEFI– and
P2Y12–mediated Rap1 activation and the respective downstream
signaling events.
In platelets activated with threshold concentrations of GPVI
agonists, CalDAG-GEFI serves as a highly sensitive response
element to Ca2 that allows for the rapid activation of Rap1.
CalDAG-GEFI–mediated Rap1 activation triggers a first wave
of integrin activation and ERK (MAPK) signaling, followed by
TxA2 release. TxA2 provides crucial feedback for the activation
of PKC and granule/ADP release. ADP in turn triggers the
second, P2Y12-dependent wave of Rap1-mediated signaling
events, leading to the sustained activation of integrins and
further release of TxA2. Higher concentrations of GPVI agonists
lead to the concomitant activation of CalDAG-GEFI and PKC,
facilitating integrin activation independent of feedback by
endogenous TxA2. It is important to note that the Gq-coupled
receptor for ADP, P2Y1,36 also contributes to PLC signaling,
thus supporting both CalDAG-GEFI– and PKC/P2Y12–
dependent platelet activation (data not shown).
Our studies identify CalDAG-GEFI as a long sought-after link
between increased [Ca2]i and the signaling mechanisms regulat-
ing integrin activation and TxA2 release. To ensure an independent
role of CalDAG-GEFI in both processes, we blocked integrin
outside-in signaling or TxA2 generation in platelets. The IIb3
blocking antibody, Leo.H4, only marginally reduced TxA2 produc-
tion in WT or knockout platelets (Figure 1F) and did not have any
effect on ERK phosphorylation, demonstrating that CalDAG-GEFI–
dependent TxA2 production is independent of CalDAG-GEFI–
Figure 4. Exogenous TxA2 restores aggregation, PKC
activation, and dense granule secretion in Cvx-
stimulated CalDAG-GEFI/ platelets. (A) Left:Aggregation
of WT platelets stimulated with low dose Cvx (100 ng/mL).
Right: Aggregation traces for CalDAG-GEFI/ platelets acti-
vated with 100 ng/mL Cvx, 500 nM U46619, or the combina-
tion of both agonists. Platelet aggregation was studied in the
presence of 75 M 2-MesAMP or 5 g/mL Ro31-8220 to
block signaling by P2Y12 and PKC, respectively. Results are
representative of 5 individual experiments. (B) CalDAG-GEFI–
deficient platelets were stimulated with low dose (LD) Cvx
(100 ng/mL) and/or U46619 (3 M) in the presence or ab-
sence of 2-MesAMP. Binding of JON/A-PE was measured to
determine the level of IIb3 activation by flow cytometry.
n	 6. **P
 .001, *P
 .05. (C) Detection of phosphorylated
PKC substrates in platelet lysates (Western blotting). WT (left
lanes) and CalDAG-GEFI/ (knockout [KO], central lanes)
platelets were stimulated for 10 minutes with 100 ng/mL Cvx,
500 nM U46619, or the combination of both agonists. Phos-
phorylation of PKC substrates, including PLEK (4), in WT
platelets pretreated with Ro31-8220 (10 g/mL) or activated
with phorbol myristate acetate (100 nM) were determined as
controls (right panel). Results are representative of 3 indepen-
dent experiments. (D) 3H-serotonin release in WT (black line,
F) or CalDAG-GEFI/ (gray line, gray triangle) platelets
activatedwith100 ng/mLCvx.After3 minutes,500 nMU46619
was added to CalDAG-GEFI/ platelets. Experiments were
performed in the presence (open symbols) or absence (filled
symbols) of the PKC inhibitor Ro31-8220 (n	 3).
Figure 5. TxA2 released from WT platelets restores aggregation of CalDAG-GEFI/ platelets. (A) Aggregation traces of platelets (108 cells) activated with 10 g/mL
collagen. The aggregation response of WT (black line), CalDAG-GEFI/ (knockout [KO], light gray line), or CalDAG-GEFI/ platelets containing 10% WT platelets (dark gray
line) was studied. WT platelets were pretreated with 1 mM aspirin (acetylsalicylic acid) before addition to CalDAG-GEFI/ platelets to inhibit TxA2 release. CalDAG-GEFI/
platelets were pretreated with 40 g/mL blocking antibody to IIb3 to demonstrate that the aggregation was integrin-dependent. Traces are representative of 3 individual
experiments. (B) Representative images showing aggregates of calcein green–labeled WT and/or calcein red–labeled KO (CalDAG-GEF/) platelets fixed with 3.7%
formaldehyde 10 minutes after stimulation and visualized with fluorescence microscopy. Scale bar 	 25 m.
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mediated integrin activation. In contrast, the defect in integrin
activation in CalDAG-GEFI/ platelets was in part secondary to
impaired TxA2 generation observed in these cells. At high agonist
concentrations, aggregation was mediated by CalDAG-GEFI and
P2Y12 signaling in a TxA2-independent manner. Aggregation of
knockout platelets activated with low dose Cvx or low dose
collagen, however, was restored by addition of exogenous TxA2
(Figures 4A and 5). TxA2 added important feedback for the
activation of PKC and thus granule/ADP release (Figure 4C-D).
The small GTPase Rap1 is the major substrate of CalDAG-
GEFI in platelets. We and others have demonstrated that CalDAG-
GEFI, P2Y12, and Rap1 are critical to integrin activation in
platelets5,17,20,37 and megakaryocytes.38,39 In other cell types, Rap1
also regulates cellular differentiation and proliferation via path-
ways that involve the regulation of the MAPK cascade.24,25 In
platelets, ERK-MAPK play a critical role in the activation of
cPLA2,30,31 a key enzyme for the generation of arachidonic acid and
thus TxA2.29 Our results provide the first evidence of a Rap1/ERK
signaling pathway in platelets and of its involvement in TxA2
generation. We found that GPVI-dependent TxA2 generation relies
entirely on the Rap1/ERK pathway, as inhibition of Rap1 activation
(CalDAG-GEFI/ platelets  2-MesAMP) or ERK signaling
(WT platelets  U0126) abolished Cvx-dependent TxA2 genera-
tion (Figure 3E). CalDAG-GEFI deficiency or inhibition of P2Y12
alone reduced TxA2 release by approximately 70%. However, a
marked difference in the kinetics of CalDAG-GEFI– and P2Y12–
mediated ERK activation was observed. CalDAG-GEFI facilitated
the rapid, but reversible activation of ERK, whereas P2Y12
signaling led to a delayed, but sustained generation of phospho-
ERK. The latter findings confirm recent studies that identified a
critical role of P2Y12 signaling for ERK activation and TxA2
generation in thrombin-activated platelets.31
Recent studies by Ginsberg and colleagues identified Rap1-
interacting adapter molecule as the potential downstream effector
of Rap1 that controls integrin activation in platelets. Their results
further suggest that Rap1-interacting adapter molecule targets talin
to the cytoplasmic domain of the integrin, a critical event in the
activation of these adhesion receptors.40,41 Little is known about the
downstream target of Rap1 that mediates the activation of ERK. In
fibroblasts, Rap1 was shown to antagonize MAPK signaling by
sequestering the serine/threonin kinase, C-Raf.42,43 In contrast,
studies in neurons demonstrated that recruitment of B-Raf to
Rap1-GTP results in the sequential activation of MEK and ERK.44
Thus, the activating or inhibitory effect of Rap1 on ERK signaling
depends on the relative abundance of B-Raf and C-Raf found in a
particular cell type.25,26,45 B-Raf is expressed in megakaryocytes
and platelets, and the B-Raf/Rap1 pathway was shown to stimulate
the ERK cascade in a model of megakaryocyte differentiation.46
C-Raf expression in platelets has also been demonstrated.47 Our
studies suggest that Rap1/B-Raf/ERK signaling may be the predomi-
nant pathway in platelets. To our knowledge, there has been only
one study on the role of Raf kinases in platelet activation, which
suggested that ERK activation in response to thrombin relies on
PKC, but not on Raf kinases.32 This conclusion, however, was
based on an in vitro kinase activity assay, but not on the functional
Figure 6. Exogenous TxA2 induces firm adhesion of
CalDAG-GEFI/ platelets to collagen. Whole blood
from WT or CalDAG-GEFI/ mice was perfused over a
collagen surface at venous shear rates (400 seconds1).
(A) Representative images showing platelets firmly adher-
ent to the collagen surface. U46619 (2 M) was added to
CalDAG-GEFI/ (knockout [KO]) whole blood immedi-
ately before the perfusion. A total of 100 M 2-MesAMP
was added 10 minutes before the perfusion. Scale
bar 	 10 m. (B) Quantification of adherent platelets.
The data are presented as the mean  SEM of the
absolute number of platelets per 0.02 mm2 surface area.
n 	 9; 3 different blood preparations. **P 
 .01.
Figure 7. A revised model of platelet activation in response to low dose
collagen. (1) A rise in [Ca2]i stimulates the CalDAG-GEFI–dependent first wave of
Rap1 and integrin activation. Activated Rap1 also triggers ERK-dependent genera-
tion of TxA2, which in turn provides critical feedback for the activation of PKC. (2) In a
next step, PKC triggers the release of granule contents, including ADP. Released
ADP signals through P2Y12/Gi to stimulate the second wave of Rap1/integrin
activation and TxA2 generation, which is required for the formation of stable
platelet-platelet contacts. Higher concentrations of GPVI agonists lead to the
concomitant activation of CalDAG-GEFI and PKC, facilitating integrin activation
independent of feedback by endogenous TxA2 (dashed line). AA indicates arachi-
donic acid; Gi, heterotrimeric G protein; P, residue phosphorylation; PL, phospholip-
ids; and TP/, thromboxane receptors.
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blockade of the kinases. Furthermore, these studies do not exclude
the possibility of a B-Raf–dependent activation in platelets stimu-
lated by agonists other than thrombin. Further studies are necessary
to understand the role of Raf kinases in Rap1-dependent MAPK
activation in platelets.
In addition to the GPVI-specific agonist Cvx, we have also
stimulated platelets with fibrillar type I collagen, a physiologic
agonist that binds to both GPVI and integrin 21. In contrast to
Cvx-activated platelets, collagen-dependent TxA2 release was only
approximately 60% reduced in 2-MesAMP–treated CalDAG-
GEFI/ platelets or MEK/ERK inhibitor-treated WT platelets.
Correlating with these results, we observed that WT platelets
stimulated with fibrillar collagen produced approximately 40%
more TxA2 compared with cells activated with high dose Cvx. The
most likely explanation for the Rap1- and ERK-independent
formation of TxA2 is outside-in signaling provided by 21.
Several in vitro and in vivo studies suggested a supportive role of
21 in collagen-induced TxA2 formation and platelet activa-
tion.48,49 Notably, Heemskerk and colleagues50 demonstrated that
platelets from 2 integrin-deficient mice and aspirin-treated WT
platelets have similar defects in their adhesion to collagen under
flow. Based on their results, they concluded that integrin 21 plays
a role in stabilizing the thrombi by enhancing GPVI-dependent
TxA2 release.50 In addition to ERK, the MAPK family members
c-Jun N-terminal kinase 1 and p38 are present in platelets.51-53
Whereas p38 signaling has been linked to cPLA2 phosphorylation
in platelets stimulated by various agonists,54,55 no such role has
been described for c-Jun N-terminal kinase 1. In addition to MAPK
signaling, Shattil and colleagues recently demonstrated that inte-
grin outside-in signaling could directly affect the enzymatic
activity of a pool of cPLA2 bound to the integrin.56 Independent of
the mechanisms regulating this second pathway for collagen-
induced TxA2 formation, our studies demonstrate that GPVI-
dependent TxA2 release requires signaling by CalDAG-GEFI and
P2Y12, which synergize at the level of Rap1 and ERK activation.
A key finding of this study is the critical role of CalDAG-GEFI
signaling in GPVI-dependent TxA2 release (Figure 1). Based on
previous reports showing that collagen-induced aggregation strongly
depends on feedback by endogenous TxA2,57,58 we speculated that
the aggregation/adhesion defects of CalDAG-GEFI/ platelets to
collagen16 could be overcome by adding exogenous TxA2. Indeed,
we were able to restore GPVI-dependent aggregation of CalDAG-
GEFI/ platelets by adding U46619 (Figure 4A) or TxA2 released
from WT platelets (Figure 5). Furthermore, addition of U46619
significantly increased the ability of CalDAG-GEFI/ platelets to
firmly adhere to a collagen surface under physiologic flow condi-
tions (Figure 6). Exogenous TxA2 supported CalDAG-GEFI–
independent, but P2Y12–dependent platelet adhesion by providing
critical feedback for GPVI-induced activation of PKC and thus
granule/ADP release (Figure 4C-D). These findings may have
important implications for the development of novel antiplatelet
agents as well as for improving existing antiplatelet strategies. Our
data identify CalDAG-GEFI as a powerful new target. Due to its
central role in the early phase of platelet activation, inhibitors of
CalDAG-GEFI will have a strong antithrombotic effect, compa-
rable with those observed with IIb3 inhibitors. On strong
thrombogenic surfaces, however, inhibition of CalDAG-GEFI can
be partially overcome by PKC/P2Y12 signaling, resulting in the
firm adhesion of platelets, and thus reduced bleeding. Our studies
also provide new insights on the mechanisms by which P2Y12
inhibitors like clopidogrel, currently one of the most successful
antiplatelet strategies in the clinic,59 prevent thrombosis. Platelets
treated with P2Y12 inhibitors rely on signaling by CalDAG-GEFI
for Rap1 activation. CalDAG-GEFI–mediated Rap1 activation
occurs rapidly, but it is reversible. Consequently, P2Y12 inhibitors
markedly reduce GPVI-induced TxA2 release, and integrin activa-
tion is transient. Under flow conditions, transient Rap1 activation
does not allow stable platelet aggregates to form.
Future studies should be directed toward a better understanding
of how P2Y12 signaling leads to Rap1 activation. In addition to
CalDAG-GEFI, the Rap1-GEFs CalDAG-GEFIII,60 PDZ-GEF1,60
and Epac1 (cyclic adenosine 5-monophosphate–GEFI)61 have
been identified in platelets and may thus be involved. Rap1
activation is also regulated by GTPase-activating proteins (GAPs).
In platelets, Rap1GAP2 was recently identified.60 In other cell
types, Gi/o signaling was shown to promote ubiquitination and
proteosomal degradation of Rap1GAP2, leading to enhanced Rap1
activity.62 However, the role of the above-mentioned RapGEFs or
Rap1GAP2 in P2Y12/Gi–dependent Rap1 activation in platelets
has not been addressed. Another area of interest will be studies
aimed at a better understanding of how Rap1 activation can be
sustained in the absence of P2Y12 signaling, or how to speed up
Rap1 activation in the absence of CalDAG-GEFI signaling.
Success in these studies could lead to a marked improvement of
antiplatelet therapy, as it would provide strategies for the develop-
ment of an antidote to P2Y12 or CalDAG-GEFI inhibitors.
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